GO:0106345 glyoxylate reductase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0106345 (glyoxylate reductase activity) is a molecular function defined as the catalysis of the reaction glycolate + NAD(P)+ = glyoxylate + NAD(P)H.
• The enzyme is best known for detoxifying glyoxylate by converting it to glycolate, thereby preventing oxalate overproduction in humans [1,4].
• Deficiency of glyoxylate reductase/hydroxypyruvate reductase (GRHPR) causes primary hyperoxaluria type 2, a rare inherited disorder characterized by recurrent kidney stones and systemic oxalosis [1,3].
• Glyoxylate reductase activity is not limited to GRHPR; other enzymes such as lactate dehydrogenase can also exhibit this activity in vitro.
• The enzyme is compartmentalized in liver mitochondria and possibly cytosol, and this localization is critical for efficient glyoxylate detoxification.
• Studying GO:0106345 requires careful distinction from related activities like hydroxypyruvate reductase and D-aspartate regulation, as GRHPR has multiple substrates [2,5].
Description
Glyoxylate reductase activity (GO:0106345) is a molecular function that catalyzes the reversible reduction of glyoxylate to glycolate using NADH or NADPH as a cofactor. This reaction is central to the detoxification of glyoxylate, a highly reactive metabolite that, if allowed to accumulate, is oxidized to oxalate, a potent promoter of calcium oxalate crystal formation [1,4]. In humans, the primary enzyme responsible for this activity is glyoxylate reductase/hydroxypyruvate reductase (GRHPR), encoded by the GRHPR gene. Loss-of-function mutations in GRHPR lead to primary hyperoxaluria type 2 (PH2), an autosomal recessive disorder characterized by excessive urinary oxalate excretion, recurrent kidney stones, and progressive renal failure [1,3]. Beyond its role in oxalate metabolism, glyoxylate reductase activity has been implicated in other metabolic pathways, including the regulation of free D-aspartate levels in mammalian cells. The enzyme is also found in diverse organisms, from algae to bacteria, where it participates in photorespiration and glyoxylate metabolism [5,7]. Understanding the mechanistic details, regulation, and disease relevance of GO:0106345 is therefore essential for researchers in nephrology, metabolic disorders, and enzymology.
glyoxylate reductase activity At A Glance
| GO ID | GO:0106345 |
|---|---|
| GO term | glyoxylate reductase activity |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Catalysis of the reversible reduction of glyoxylate to glycolate using NAD(P)H as cofactor |
| Reaction | glycolate + NAD(P)+ = glyoxylate + NAD(P)H |
| Cofactors | NADH or NADPH |
| Substrates | Glyoxylate, glycolate |
| Associated enzyme | Glyoxylate reductase/hydroxypyruvate reductase (GRHPR) |
| Disease relevance | Primary hyperoxaluria type 2 (PH2) |
What Is GO:0106345?
Glyoxylate reductase activity (GO:0106345) is defined by the Gene Ontology as the catalysis of the reaction: glycolate + NAD(P)+ = glyoxylate + NAD(P)H. In other words, it is the enzyme activity that interconverts glycolate and glyoxylate using either NAD+ or NADP+ as an electron acceptor. This activity is reversible and can function in either direction depending on substrate availability and cellular redox state.
Why Is glyoxylate reductase activity Important in Cell Biology?
Glyoxylate reductase activity is critically important because it prevents the accumulation of glyoxylate, a metabolite that is readily oxidized to oxalate. Oxalate is a key component of kidney stones and can cause systemic oxalosis when produced in excess [1,4]. In humans, inherited deficiency of GRHPR, the enzyme responsible for this activity, results in primary hyperoxaluria type 2, a severe disorder with significant morbidity and mortality [1,3]. Moreover, glyoxylate reductase activity is not confined to humans; it plays roles in plant photorespiration and microbial metabolism, making it a target for agricultural and biotechnological research [5,7]. The enzyme's ability to use both NADH and NADPH links it to cellular redox homeostasis and broader metabolic networks [2,4].
• Prevents oxalate overproduction by detoxifying glyoxylate, reducing the risk of kidney stone formation.
• Deficiency causes primary hyperoxaluria type 2, a rare but severe inherited metabolic disorder [1,3].
• Provides a diagnostic marker for PH2 through measurement of enzyme activity in blood mononuclear cells.
• Contributes to the regulation of free D-aspartate levels in mammalian cells, linking it to neurotransmission.
• Exhibits compartment-specific localization in liver mitochondria, which is crucial for efficient glyoxylate detoxification.
• Found in diverse organisms, including algae and bacteria, where it participates in photorespiration and glyoxylate cycle [5,7].
• Can be catalyzed by other enzymes such as lactate dehydrogenase, indicating metabolic redundancy.
• Serves as a potential target for therapeutic strategies aimed at reducing oxalate production in hyperoxaluria.
• Its dual cofactor specificity (NADH/NADPH) connects it to cellular redox and energy metabolism.
• Studying its kinetics and substrate specificity aids in understanding enzyme evolution and metabolic engineering.
What Happens During glyoxylate reductase activity?
Substrate Binding and Cofactor Recruitment
In simple terms: The enzyme grabs glyoxylate and a helper molecule called NADH or NADPH.
The reaction begins with the binding of glyoxylate and a reduced nicotinamide cofactor (NADH or NADPH) to the active site of glyoxylate reductase. The enzyme facilitates the transfer of a hydride ion from the cofactor to the carbonyl carbon of glyoxylate, reducing it to glycolate. This step is reversible and depends on the relative concentrations of substrates and products.
Catalytic Reduction of Glyoxylate to Glycolate
In simple terms: The enzyme turns glyoxylate into glycolate, a less harmful molecule.
The reduction of glyoxylate to glycolate is the central catalytic event. This conversion is essential for detoxification because glyoxylate can otherwise be oxidized to oxalate, which is insoluble and forms crystals. The enzyme uses either NADH or NADPH as the electron donor, with a preference that may vary among species and isoforms.
Compartmentalization and Metabolic Context
In simple terms: This reaction happens in specific parts of the cell, mainly mitochondria in liver cells.
In human liver, glyoxylate reductase activity has been definitively localized to mitochondria, where it plays a key role in compartment-specific detoxification of glyoxylate. This localization ensures that glyoxylate produced in mitochondria is efficiently converted to glycolate before it can diffuse and be oxidized to oxalate. Cytosolic isoforms may also exist, contributing to overall glyoxylate handling.
Reversibility and Role in Gluconeogenesis
In simple terms: The reaction can go backwards, helping to make other molecules when needed.
The reaction catalyzed by glyoxylate reductase is reversible. In the reverse direction, glycolate is oxidized to glyoxylate, which can then enter gluconeogenic pathways or be transaminated to glycine. This reversibility allows the enzyme to participate in both detoxification and biosynthetic processes, depending on metabolic demands.
Key Genes Involved in GO:0106345 glyoxylate reductase activity
The following genes and proteins are directly associated with glyoxylate reductase activity (GO:0106345) or its regulation, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GRHPR | Primary enzyme catalyzing glyoxylate reductase activity in humans | Mutations cause primary hyperoxaluria type 2; target for gene therapy [1,3] |
| LDHA | Lactate dehydrogenase A, exhibits glyoxylate reductase activity in vitro | Potential alternative route for glyoxylate metabolism; studied in cancer metabolism |
| HAO1 | Hydroxyacid oxidase 1, produces glyoxylate in peroxisomes | Upstream of glyoxylate reductase; target for RNAi therapy in PH1 |
| AGXT | Alanine:glyoxylate aminotransferase, detoxifies glyoxylate in peroxisomes | Deficiency causes primary hyperoxaluria type 1; interacts with glyoxylate pool |
| GRHPR (mitochondrial) | Mitochondrial isoform of glyoxylate reductase | Compartment-specific detoxification; identified in human liver mitochondria |
| DDO | D-aspartate oxidase, produces glyoxylate from D-aspartate | Linked to GRHPR in regulating D-aspartate levels |
| GLO1 | Glyoxalase 1, related to glyoxylate metabolism | May influence glyoxylate levels indirectly |
| PIPOX | Pipecolate oxidase, produces glyoxylate | Contributes to glyoxylate pool; potential modifier |
| SARDH | Sarcosine dehydrogenase, produces glyoxylate | Mitochondrial source of glyoxylate |
| DMGDH | Dimethylglycine dehydrogenase, produces glyoxylate | Mitochondrial source of glyoxylate |
| HOGA1 | 4-hydroxy-2-oxoglutarate aldolase, involved in glyoxylate metabolism | Mutations cause primary hyperoxaluria type 3 |
| SLC26A6 | Oxalate transporter | Affects oxalate excretion; modifier of hyperoxaluria |
| SLC26A1 | Sulfate/oxalate transporter | Involved in oxalate homeostasis |
| CLCN5 | Chloride/proton exchanger | May influence oxalate transport in kidney |
| NHERF1 | Scaffold protein regulating oxalate transport | Potential modifier of hyperoxaluria |
| OPN | Osteopontin, inhibitor of calcium oxalate crystallization | Modulates stone formation in hyperoxaluria |
| CD44 | Cell surface receptor involved in crystal adhesion | Potential therapeutic target in oxalate nephropathy |
| MGP | Matrix Gla protein, inhibitor of vascular calcification | May be affected in systemic oxalosis |
How Is glyoxylate reductase activity Regulated?
Glyoxylate reductase activity is regulated at multiple levels. Enzyme abundance is controlled by GRHPR gene expression, which can be influenced by metabolic state and tissue-specific factors. The enzyme's activity is also modulated by substrate availability, particularly glyoxylate and glycolate concentrations, and by the cellular redox ratio of NADH/NAD+ and NADPH/NADP+. In mitochondria, compartmentalization ensures that glyoxylate produced by sarcosine dehydrogenase and dimethylglycine dehydrogenase is efficiently reduced. Additionally, post-translational modifications and protein-protein interactions may affect enzyme stability and function, though specific mechanisms remain to be fully elucidated.
glyoxylate reductase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GRHPR | Primary hyperoxaluria type 2 | GRHPR knockout mouse; patient-derived iPSCs; liver-specific KO |
| LDHA | Glyoxylate reductase activity in cancer metabolism | LDHA overexpression/knockdown cell lines; metabolic flux analysis |
| HAO1 | Primary hyperoxaluria type 1 (glyoxylate overproduction) | HAO1 KO mice; RNAi knockdown in hepatocytes |
| AGXT | Primary hyperoxaluria type 1 | AGXT KO mice; cellular models of peroxisomal dysfunction |
| DDO | D-aspartate metabolism and neurotransmission | DDO KO mice; neuronal cell lines with GRHPR modulation |
Primary Hyperoxaluria Type 2 (PH2)
Primary hyperoxaluria type 2 is an autosomal recessive disorder caused by mutations in the GRHPR gene, leading to deficient glyoxylate reductase activity. The loss of enzyme function results in increased conversion of glyoxylate to oxalate, which forms insoluble calcium oxalate crystals in the kidneys and urinary tract [1,3]. Patients typically present with recurrent kidney stones, nephrocalcinosis, and progressive renal failure. Systemic oxalosis can occur in advanced stages, affecting the heart, bones, and eyes. Diagnosis is confirmed by measuring glyoxylate reductase activity in blood mononuclear cells or by genetic testing.
Hyperoxaluria and Kidney Stone Disease
Even partial reductions in glyoxylate reductase activity can contribute to hyperoxaluria, a condition of elevated urinary oxalate. This increases the risk of calcium oxalate kidney stones, a common and painful condition. While PH2 is rare, milder variants may predispose to idiopathic stone formation. Understanding the regulation of GO:0106345 is therefore relevant to broader nephrolithiasis research [1,6].
Neurological Implications via D-Aspartate Regulation
Recent studies have shown that GRHPR, through its glyoxylate reductase activity, regulates the free D-aspartate level in mammalian cells. D-Aspartate is a neurotransmitter and neuromodulator involved in memory and learning. Dysregulation of D-aspartate has been implicated in schizophrenia and other neuropsychiatric disorders. Thus, glyoxylate reductase activity may have unexpected roles in brain function, warranting further investigation.
From glyoxylate reductase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GRHPR cause hyperoxaluria? | GRHPR knockout mouse or liver-specific KO |
| Can a point mutation in GRHPR alter substrate specificity? | Knock-in mouse expressing mutant GRHPR (e.g., missense mutation from PH2 patients) |
| Does mitochondrial targeting of GRHPR affect glyoxylate detoxification? | Knock-in of tagged GRHPR (e.g., FLAG or GFP) to track localization |
| Can overexpression of GRHPR reduce oxalate production? | Adenoviral or AAV-mediated GRHPR overexpression in hepatocytes |
| What is the role of GRHPR in D-aspartate regulation? | GRHPR KO neuronal cell lines; D-aspartate measurement |
| Can CRISPR screening identify modifiers of glyoxylate reductase activity? | Genome-wide CRISPR knockout library in liver cells with glyoxylate stress |
How to Study the glyoxylate reductase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Spectrophotometric NADH oxidation assay | Glyoxylate reductase enzyme activity | Diagnosis of PH2; kinetic studies |
| Sanger sequencing | Mutations in GRHPR gene | Genetic confirmation of PH2 |
| CRISPR knockout screening | Genes affecting glyoxylate metabolism | Discovery of novel regulators |
| 13C metabolic flux analysis | Flux through glyoxylate reductase reaction | Quantifying pathway activity in cells |
| Immunofluorescence | Subcellular localization of GRHPR | Mitochondrial vs. cytosolic distribution |
| Western blot | Protein expression levels of GRHPR | Assessing enzyme abundance |
| qRT-PCR | mRNA expression of GRHPR | Gene expression studies |
| D-aspartate measurement (HPLC) | D-aspartate levels | Neurochemical studies linking GRHPR to neurotransmission |
Enzyme Activity Assays
Glyoxylate reductase activity is typically measured spectrophotometrically by monitoring the oxidation of NADH or NADPH at 340 nm in the presence of glyoxylate. This assay can be performed on cell lysates, tissue homogenates, or purified enzyme preparations. It is the gold standard for diagnosing PH2 from blood mononuclear cells.
Genetic and Genomic Approaches
Sanger sequencing or next-generation sequencing of the GRHPR gene is used to identify mutations in patients with hyperoxaluria. CRISPR-Cas9 knockout screens can identify genes that modify glyoxylate reductase activity or oxalate production. RNA-seq can reveal expression changes in GRHPR and related metabolic genes under different conditions.
Metabolic Flux Analysis
Stable isotope tracing with 13C-labeled glyoxylate or glycolate can quantify flux through the glyoxylate reductase reaction in living cells or perfused organs. This method provides dynamic information about pathway activity and compartmentalization.
Localization and Imaging
Immunofluorescence or live-cell imaging of tagged GRHPR (e.g., GFP fusion) can determine subcellular localization, particularly mitochondrial vs. cytosolic. Mitochondrial isolation followed by activity assays confirms compartment-specific function.
How CRISPR Can Be Used to Study GO:0106345 glyoxylate reductase activity
Knockout
CRISPR-Cas9 knockout of GRHPR in human cell lines (e.g., HepG2 or HEK293) creates a model of primary hyperoxaluria type 2. These cells exhibit reduced glyoxylate reductase activity and increased oxalate production, making them useful for testing therapeutic interventions. Knockout mice are also available for in vivo studies of oxalate nephropathy.
Point Mutation
Introducing specific missense mutations found in PH2 patients (e.g., c.103delG, c.403_404+2delAA) into the endogenous GRHPR locus using CRISPR prime editing or homology-directed repair allows researchers to study the functional impact of individual mutations on enzyme activity and stability. This approach provides a more physiologically relevant model than overexpression.
Knock-in
Knock-in of a tagged GRHPR (e.g., FLAG, HA, or GFP) at the endogenous locus enables tracking of protein localization, interaction partners, and turnover without altering expression levels. This is particularly useful for studying mitochondrial targeting sequences and compartment-specific functions.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of GRHPR can increase glyoxylate reductase activity, potentially reducing oxalate production in cellular models of hyperoxaluria. Overexpression studies help establish causality and may inform gene therapy strategies.
How EDITGENE Supports glyoxylate reductase activity Research
Researchers studying glyoxylate reductase activity-related genes often need to determine whether a candidate gene is causally involved in glyoxylate detoxification, oxalate production, or related metabolic pathways. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell and animal models, enabling rigorous functional studies of GO:0106345 and its associated genes.
Contact EDITGENE today to design your custom CRISPR model for glyoxylate reductase activity research.
Frequently Asked Questions About glyoxylate reductase activity
What is glyoxylate reductase activity?
Glyoxylate reductase activity (GO:0106345) is the enzyme activity that catalyzes the reversible conversion of glyoxylate to glycolate using NADH or NADPH as a cofactor.
What genes are involved in glyoxylate reductase activity?
The primary gene is GRHPR, which encodes glyoxylate reductase/hydroxypyruvate reductase. Other genes like LDHA can also exhibit this activity in vitro [1,8].
What diseases are associated with glyoxylate reductase deficiency?
Deficiency causes primary hyperoxaluria type 2, characterized by recurrent kidney stones and systemic oxalosis [1,3].
How is glyoxylate reductase activity measured?
It is typically measured spectrophotometrically by monitoring NADH or NADPH oxidation at 340 nm in the presence of glyoxylate [1,3].
Where is glyoxylate reductase located in the cell?
In human liver, it is primarily localized to mitochondria, with possible cytosolic isoforms.
Can glyoxylate reductase activity be targeted for therapy?
Yes, enhancing its activity or replacing the deficient enzyme are potential therapeutic strategies for primary hyperoxaluria type 2 [1,6].
What is the reaction catalyzed by glyoxylate reductase?
The reaction is: glycolate + NAD(P)+ = glyoxylate + NAD(P)H.
Is glyoxylate reductase the same as hydroxypyruvate reductase?
GRHPR has both glyoxylate reductase and hydroxypyruvate reductase activities; they are distinct but catalyzed by the same enzyme.
What model organisms are used to study glyoxylate reductase?
Mouse models with GRHPR knockout, cell lines like HepG2, and patient-derived iPSCs are commonly used [1,4].
How does glyoxylate reductase relate to D-aspartate?
GRHPR regulates free D-aspartate levels in mammalian cells, linking glyoxylate metabolism to neurotransmission.
Conclusion
Glyoxylate reductase activity (GO:0106345) is a fundamental metabolic function that protects against oxalate overproduction and is essential for human health. Its deficiency leads to primary hyperoxaluria type 2, a severe disorder with limited treatment options. Ongoing research into the enzyme's structure, regulation, and compartmentalization continues to reveal new insights, including its role in D-aspartate metabolism. CRISPR-based models are invaluable for dissecting the molecular mechanisms of GO:0106345 and for developing targeted therapies.
References
- 1. Adam MP et al.. 1993. Primary Hyperoxaluria Type 2.. PMID: 20301742
- 2. Katane M et al.. 2021. Glyoxylate reductase/hydroxypyruvate reductase regulates the free d-aspartate level in mammalian cells.. J Cell Biochem 122(11):1639-1652 PMID: 34289161
- 3. Knight J et al.. 2006. Glyoxylate reductase activity in blood mononuclear cells and the diagnosis of primary hyperoxaluria type 2.. Nephrol Dial Transplant 21(8):2292-5 PMID: 16597637
- 4. Garrelfs SF et al.. 2024. Glyoxylate reductase: Definitive identification in human liver mitochondria, its importance for the compartment-specific detoxification of glyoxylate.. J Inherit Metab Dis 47(2):280-288 PMID: 38200664
- 5. Husic DW et al.. 1987. NADH:hydroxypyruvate reductase and NADPH:glyoxylate reductase in algae: partial purification and characterization from Chlamydomonas reinhardtii.. Arch Biochem Biophys 252(2):396-408 PMID: 3545081
- 6. Murad S et al.. 2017. ENDOCRINE MANIFESTATIONS OF PRIMARY HYPEROXALURIA.. Endocr Pract 23(12):1414-1424 PMID: 29144803
- 7. Majumder TR et al.. 2024. Comparative studies on substrate specificity of succinic semialdehyde reductase from Gluconobacter oxydans and glyoxylate reductase from Acetobacter aceti.. Biosci Biotechnol Biochem 88(9):1069-1072 PMID: 38871868
- 8. Sawaki S et al.. 1966. Glyoxylate reductase activity of lactate dehydrogenase.. Nature 210(5031):91 PMID: 4289161
